John R. Stuelpnagel is Director at 10x Genomics, Inc. (TXG). They have made 40 open-market trades across 1 company since 2005, most recently 2026-09-03.
CIK 0001189140
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 40 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ILMN | 337,836 | $88.7M |
| TXG | 328,436 | $22.9M |
| Total | $111.6M |
Shares reported on the most recent Form 4, priced at the 2026-09-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TXG | SELL | 2026-09-03 | 2026-09-08 | $61.75 | $1.2M | +19.3% | +20.3% | — |
| TXG | SELL | 2026-08-11 | 2026-08-13 | $57.75 | $1.2M | +12.1% | +21.5% | — |
| TXG | SELL | 2023-06-05 | 2023-06-07 | $54.89 | $549K | +7.9% | +0.4% | -2.3% |
| TXG | SELL | 2021-12-30 | 2022-01-04 | $150.92 | $1.5M | -25.5% | -35.2% | -41.0% |
| TXG | SELL | 2021-12-01 | 2021-12-03 | $151.16 | $756K | +2.4% | +6.3% | -46.0% |
| TXG | SELL | 2021-11-16 | 2021-11-18 | $158.82 | $1.6M | -3.7% | -7.3% | -36.6% |
| TXG | SELL | 2021-11-01 | 2021-11-03 | $163.56 | $1.5M | -9.7% | -21.2% | -43.2% |
| TXG | SELL | 2021-10-18 | 2021-10-20 | $150.67 | $753K | +0.4% | -8.0% | -43.1% |
| TXG | SELL | 2021-10-07 | 2021-10-12 | $150.18 | $751K | +2.5% | +4.9% | -20.2% |
| TXG | SELL | 2021-09-16 | 2021-09-20 | $156.45 | $1.3M | -10.3% | -0.4% | -14.5% |
| TXG | SELL | 2021-09-01 | 2021-09-03 | $177.60 | $1.2M | -13.3% | -22.0% | -19.6% |
| TXG | SELL | 2021-08-16 | 2021-08-18 | $159.57 | $1.5M | +11.3% | +4.7% | +2.8% |
| TXG | SELL | 2021-08-02 | 2021-08-04 | $180.27 | $1.3M | -9.8% | +4.4% | -8.7% |
| TXG | SELL | 2021-07-16 | 2021-07-20 | $170.33 | $1.5M | +1.0% | -15.0% | -15.1% |
| TXG | SELL | 2021-07-01 | 2021-07-06 | $191.64 | $958K | -11.9% | -9.8% | -25.9% |
| TXG | SELL | 2021-06-17 | 2021-06-21 | $199.39 | $997K | -4.0% | -6.9% | -18.2% |
| TXG | SELL | 2021-06-01 | 2021-06-03 | $173.88 | $1.7M | +9.9% | +11.1% | +3.8% |
| TXG | SELL | 2021-05-17 | 2021-05-19 | $141.53 | $1.3M | +15.5% | +27.5% | +6.7% |
| TXG | SELL | 2021-05-03 | 2021-05-05 | $191.67 | $2.2M | -13.5% | +8.3% | +7.4% |
| TXG | SELL | 2021-04-16 | 2021-04-19 | $192.87 | $2.0M | +5.3% | -19.4% | -7.9% |
| TXG | SELL | 2021-04-01 | 2021-04-02 | $184.65 | $2.4M | +2.0% | +2.2% | +0.8% |
| TXG | SELL | 2021-03-17 | 2021-03-18 | $169.49 | $1.9M | -1.1% | +9.9% | +13.0% |
| TXG | SELL | 2021-03-01 | 2021-03-03 | $183.53 | $2.1M | -1.2% | +11.2% | +2.7% |
| TXG | SELL | 2021-02-16 | 2021-02-18 | $192.91 | $2.2M | -2.5% | -6.4% | -21.1% |
| TXG | SELL | 2021-02-01 | 2021-02-03 | $176.02 | $2.5M | +5.6% | -14.6% | +1.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.